Reneo Pharma terminates CDO Ashley Hall amid planned merger with OnKure

OnKure Therapeutics, Inc.

Ashley F. Hall, Chief Development Officer, terminated effective Sept 13, 2024.
Termination linked to planned merger with OnKure, Inc. and cessation of drug development.
Hall will receive severance benefits under previously disclosed severance plan.
Merger with OnKure is expected to shift company away from historical drug development.
Gregory J. Flesher remains CEO; no replacement for CDO announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ashley F. Hall

Chief Development Officer

OKUR · OnKure Therapeutics, Inc.

Effective: 2024-09-13
Filed: September 13, 2024, 7:59 PM ET

the Company terminated the employment of Ashley F. Hall, J.D., the Company’s Chief Development Officer, effective as of September 13, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ashley F. Hall was terminated as Chief Development Officer at OnKure Therapeutics, Inc..

Action: terminated
Role: Chief Development Officer

Exact text from the filing

the Company terminated the employment of Ashley F. Hall, J.D., the Company’s Chief Development Officer, effective as of September 13, 2024.

View on SEC.gov

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-218879

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.